Samrotamab

• CAT Number: I040368
• CAS Number: 2052591-32-7
• Purity: ≥95%

Samrotamab(CAT: I040368) is an investigational bispecific antibody engineered to target both the epidermal growth factor receptor (EGFR) and CD3, a key component of the T cell receptor complex. By simultaneously binding to EGFR-expressing tumor cells and CD3 on T cells, Samrotamab facilitates T cell-mediated cytotoxicity against cancer cells. This dual-targeting mechanism enhances immune cell recruitment and activation directly at the tumor site, offering a promising strategy for treating EGFR-positive solid tumors. Samrotamab is under clinical evaluation for its efficacy and safety profile, and represents a novel immunotherapeutic approach within the bispecific T cell engager (BiTE) antibody platform.